推进公共卫生患者安全的方法

At least, that’s what the average person would think after leaving a conversation with two of AbbVie’s leaders in pharmacovigilance, or “drug safety” for the benefit of patients.

It could be because of the unusual career path of AbbVie’s head of pharmacovigilance and patient safety Linda Scarazzini, RPh, M.D., who went from chief medical resident at a prestigious university hospital to patient safety leader at the FDA before joining AbbVie.

It could be because of the colorful décor in the office of Fabio Lievano, M.D., AbbVie’s vice president of safety science: T-shirts from his favorite safety conferences tacked up on the wall, next to awards recognizing his work bringing vaccines to war zones.

Or, it could be the fact that these leaders are so passionate about keeping patients safe that they joined forces to write the book “Pharmacovigilance: A Practical Approach,” tailored to the next generation of safety scientists.

Whatever it is, both Scarazzini and Lievano have developed a cutting-edge patient safety group at AbbVie that goes far beyond compliance and instead places patient needs at the center.

这不是传统的患者安全组,只专注于实现卫生保健行业的规章制度。

至少,这是一般人认为离开对话后药物警戒与AbbVie的两个领导人,或“药品安全”,造福患者。

这可能是因为AbbVie不同寻常的职业道路的药物警戒和患者安全主管琳达Scarazzini,气道,医学博士,他从首席医疗居民在著名的大学医院病人安全领袖FDA加入AbbVie之前。

这可能是因为丰富多彩的装饰法比奥Lievano办公室,医学博士,AbbVie安全科学的副总裁:t恤从他最喜欢的安全会议钉在墙上,旁边奖项承认他的工作将疫苗战区。

或者,它可能是这些领导人如此热衷于保护病人的安全,他们联手写这本书“药物警戒:一个实际的方法,根据安全的下一代科学家。

不管它是什么,和Scarazzini Lievano已经开发出一种先进的病人安全小组AbbVie远远超出合规,而地方病人需要的中心。

While compliance is still an important aspect, today patient safety is far more holistic and more integrated. The field of pharmacovigilance has expanded and relies on delivering rich, data-driven information about medications to patients, medical practitioners and regulators, an evolution AbbVie anticipated and embraces, Scarazzini says.

“We have to give the patient the most meaningful information – they’re demanding this, and we’ve taken a proactive approach to deliver on patient needs,” she says. “Bringing my experience from the FDA, I’ve been able to bring that approach and build an industry-leading safety organization.”

This shift in mindset is reflected in AbbVie’s patient safety group, representing over 500 dedicated health care and safety professionals. About half of the group is safety operations, which includes nurses, pharmacists and the people who have a direct line to patients around the globe.

退一步在时间的几年中,和患者安全领域几乎只关注合规后,规定和报告指南由政府机构制定。

而合规仍然是一个重要方面,今天病人安全更全面和综合。药物警戒领域的扩大,依靠提供丰富的数据驱动的药物对病人的信息,医疗从业者和管理者,一个进化AbbVie预期和拥抱,Scarazzini说。

“我们必须给病人最有意义的信息,他们要求这个,我们已经采取积极的方法来实现病人的需求,”她说。“把我的经验来自美国食品和药物管理局,我已经能够把这种方法和建立一个行业领先的安全组织”。

这种心态的转变是反映在AbbVie患者安全组,代表超过500个专用的卫生保健和安全专业人士。大约一半的集团是安全操作,包括护士、药剂师和人直达世界各地的病人。

Lievano draws from his varied background in medicine and public health, including his previous roles across the globe with the U.S. Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO).

As a leader at WHO, Lievano was embedded during the Bosnian War and tasked with rebuilding health care services. At the CDC, he focused on measles control and elimination worldwide. After more than a decade in public health, the natural next step was to bring this firsthand knowledge to the pharmaceutical industry, Lievano says.

“I thought, I need to go where the medicines are developed,” he says. “And the science we do here, it’s the best way to protect patients and enhance health care globally.”

病人安全的关键是科学安全Lievano领导的研究小组,专注于其分析药物和由数据科学家、医生和流行病学家、研究疾病在人群的人。这个团队收集并分析全球卫生和中介数据和病人的影响,识别趋势带回AbbVie内科学家的墙壁。

Lievano吸引各种医学和公共卫生的背景,包括他以前的角色在全球与美国疾病控制和预防中心(CDC)和世界卫生组织(世卫组织)。

在他作为一个领导者,Lievano嵌入在波斯尼亚战争期间,负责重建医疗服务。在疾控中心,他关注全球麻疹控制和消除。在公共卫生十多年后,下一步自然是给医药行业带来这第一手知识,Lievano说。

“我想,我需要去开发的药物,”他说。”,我们做的科学,这是最好的方式来保护病人和提高全球卫生保健。”

“The future is precision pharmacovigilance, where you’ll take medicine based on your DNA,” he says. “As an industry, we’ll rely on genomics and take it to the point where we can predict what will happen in the body.”

Precision pharmacovigilance is just one important area within safety science around the globe, illustrating the need for a future-looking approach driven by what’s best for patients, Scarazzini says.

“We built our pharmacovigilance team around data science and patient insights, relying on evidence and the strong voices of patients to bring us into the future,” she says.

激光聚焦于患者强调在日益精密医学领域,与患者安全交织在一起,Lievano说。

“未来是精密药物警戒,你吃药基于DNA,”他说。“作为一个行业,我们会依赖基因组学和接受它,我们可以预测在体内会发生什么。”

精密药物警戒只是一个重要的领域内全球安全科学,说明需要未来看方法由什么对病人最好,Scarazzini说。

“我们建立药物警戒数据科学团队和患者的见解,依靠证据和病人的强大的声音把我们带到未来,”她说。